The surrogate-imaging 111In-DTPA-anti-PD-L1-BC demonstrated pharmacokinetic differences as compared to 225Ac-DOTA-anti-PD-L1-BC, particularly in the liver, kidneys, and tumor. The gene discussed is CD274; the disease is neoplasm.